192 related articles for article (PubMed ID: 16412651)
1. Quantitative structure-activity relationship of spirosuccinimide type aldose reductase inhibitors diminishing sorbitol accumulation in vivo.
Ko K; Won H; Won Y
Bioorg Med Chem; 2006 May; 14(9):3090-7. PubMed ID: 16412651
[TBL] [Abstract][Full Text] [Related]
2. Quantitative structure and aldose reductase inhibitory activity relationship of 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone derivatives.
Ko K; Won Y
Bioorg Med Chem; 2005 Mar; 13(5):1445-52. PubMed ID: 15698760
[TBL] [Abstract][Full Text] [Related]
3. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.
Negoro T; Murata M; Ueda S; Fujitani B; Ono Y; Kuromiya A; Komiya M; Suzuki K; Matsumoto J
J Med Chem; 1998 Oct; 41(21):4118-29. PubMed ID: 9767647
[TBL] [Abstract][Full Text] [Related]
4. Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation.
Chatzopoulou M; Patsilinakos A; Vallianatou T; Prnova MS; Zakelj S; Ragno R; Stefek M; Kristl A; Tsantili-Kakoulidou A; Demopoulos VJ
Bioorg Med Chem; 2014 Apr; 22(7):2194-207. PubMed ID: 24630695
[TBL] [Abstract][Full Text] [Related]
5. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
Saraswat M; Muthenna P; Suryanarayana P; Petrash JM; Reddy GB
Asia Pac J Clin Nutr; 2008; 17(4):558-65. PubMed ID: 19114390
[TBL] [Abstract][Full Text] [Related]
6. Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability.
Kurono M; Fujii A; Murata M; Fujitani B; Negoro T
Biochem Pharmacol; 2006 Jan; 71(3):338-53. PubMed ID: 16324683
[TBL] [Abstract][Full Text] [Related]
7. A neural networks-based drug discovery approach and its application for designing aldose reductase inhibitors.
Hu L; Chen G; Chau RM
J Mol Graph Model; 2006 Jan; 24(4):244-53. PubMed ID: 16226911
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and efficacy of structurally related spirohydantoin and spirosuccinimide aldose reductase inhibitors.
Park YH; Barker R; Griffin B; Barratt D; DuPriest M; Brazzell K; York B; Mayer P
Xenobiotica; 1992 May; 22(5):543-50. PubMed ID: 1413869
[TBL] [Abstract][Full Text] [Related]
9. Exploring structural requirements for aldose-reductase inhibition by 2,4-dioxo-5-(naphth-2-ylmethylene)-3-thiazolidinyl acetic acids and 2-thioxo analogues: Fujita-Ban and Hansch approach.
Soni LK; Kaskhedikar SG
Arch Pharm (Weinheim); 2006 Jun; 339(6):327-31. PubMed ID: 16622827
[TBL] [Abstract][Full Text] [Related]
10. An inhibitor of aldose reductase and sorbitol accumulation from Anthocepharus chinensis.
Haraguchi H; Kanada M; Fukuda A; Naruse K; Okamura N; Yagi A
Planta Med; 1998 Feb; 64(1):68-9. PubMed ID: 9491768
[TBL] [Abstract][Full Text] [Related]
11. Exploration of QSAR modelling techniques and their combination to rationalize the physicochemical characters of nitrophenyl derivatives towards aldose reductase inhibition.
Soni LK; Gupta AK; Kaskhedikar SG
J Enzyme Inhib Med Chem; 2009 Aug; 24(4):1002-7. PubMed ID: 19514863
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.
Iqbal Z; Morahan G; Arooj M; Sobolev AN; Hameed S
Eur J Med Chem; 2019 Apr; 168():154-175. PubMed ID: 30818176
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of ganoderma acids from Ganoderma lucidum as aldose reductase inhibitors.
Fatmawati S; Shimizu K; Kondo R
Bioorg Med Chem Lett; 2011 Dec; 21(24):7295-7. PubMed ID: 22047696
[TBL] [Abstract][Full Text] [Related]
14. Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase.
Kurono M; Fujiwara I; Yoshida K
Biochemistry; 2001 Jul; 40(28):8216-26. PubMed ID: 11444967
[TBL] [Abstract][Full Text] [Related]
15. Structure-based optimization of aldose reductase inhibitors originating from virtual screening.
Eisenmann M; Steuber H; Zentgraf M; Altenkämper M; Ortmann R; Perruchon J; Klebe G; Schlitzer M
ChemMedChem; 2009 May; 4(5):809-19. PubMed ID: 19301313
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of rhetsinine isolated from Evodia rutaecarpa on aldose reductase activity.
Kato A; Yasuko H; Goto H; Hollinshead J; Nash RJ; Adachi I
Phytomedicine; 2009 Mar; 16(2-3):258-61. PubMed ID: 17498942
[TBL] [Abstract][Full Text] [Related]
17. Predictive QSAR modeling of aldose reductase inhibitors using Monte Carlo feature selection.
Nantasenamat C; Monnor T; Worachartcheewan A; Mandi P; Isarankura-Na-Ayudhya C; Prachayasittikul V
Eur J Med Chem; 2014 Apr; 76():352-9. PubMed ID: 24589490
[TBL] [Abstract][Full Text] [Related]
18. Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
Ishibashi Y; Matsui T; Matsumoto T; Kato H; Yamagishi S
Diab Vasc Dis Res; 2016 Jul; 13(4):312-5. PubMed ID: 27190083
[TBL] [Abstract][Full Text] [Related]
19. Quantitative structure-activity relationship to predict differential inhibition of aldose reductase by flavonoid compounds.
Fernández M; Caballero J; Helguera AM; Castro EA; González MP
Bioorg Med Chem; 2005 May; 13(9):3269-77. PubMed ID: 15809162
[TBL] [Abstract][Full Text] [Related]
20. A high dimensional QSAR study on the aldose reductase inhibitory activity of some flavones: topological descriptors in modeling the activity.
Prabhakar YS; Gupta MK; Roy N; Venkateswarlu Y
J Chem Inf Model; 2006; 46(1):86-92. PubMed ID: 16426043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
